Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Philippines Manufacturing PMI Hits Nine-Month High Despite Weak Confidence Outlook 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Indian Rupee Strengthens Sharply After U.S.-India Trade Deal Announcement 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance 
Gold Prices Stabilize in Asian Trade After Sharp Weekly Losses Amid Fed Uncertainty 
Japan’s Agricultural, Forestry and Fishery Exports Hit Record High in 2025 Despite Tariffs 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
The Japanese Ministry of Health, Labor and Welfare has granted priority review status to the Alzheimer’s disease drug, lecanemab, of Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc.
Once the priority status has been granted, the target total review period is shortened.
Lecanemab was recently granted accelerated approval in the US.
A late-stage study showed the drug reduced the rate of cognitive decline in patients with early Alzheimer’s by 27 percent, compared with a placebo.
Similar experimental medications have largely all failed in the past.
Eisai also requested complete U.S. approval of the medication earlier this month. Food and Drug Administration (FDA) as a treatment for patients with neurodegenerative disease in its early stages.
